T1	Participants 66 161	children, adolescents, and adults with mental retardation and pervasive developmental disorders
T2	Participants 241 347	children, adolescents, and adults with mental retardation (MR) and pervasive developmental disorders (PDD)
T3	Participants 600 650	children, adolescents, and adults with MR and PDDs
T4	Participants 686 765	21-subject subset during the course of a double-blind, placebo-controlled trial
T5	Participants 881 936	children and adolescents (n=10), mean age of 12.5 years
T6	Participants 1070 1100	adults, mean age of 35.3 years
T7	Participants 1585 1591	adults
T8	Participants 1593 1600	females
T9	Participants 1646 1651	males
